Publications

Pembrolizumab and Olaparib in HRD Metastatic Pancreatic Cancer: The POLAR Trial

Park W (Corresponding Author), O’Reilly E, et al.

Nature Medicine

POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer

Park W, Umeda S, Hilmi M, O'Connor C, Sharma R, Tezcan N, Zhang H, Zhu Y, et al.

bioRxiv

Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort

Keane F, O'Connor C, Moss D, Chou JF, Perry MA, Crowley F, Saxena P, Chan A, et al.

J Natl Cancer Inst

Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma

Keane F, Saadat LV, O'Connor CA, Chou JF, Bowman AS, Xu F, Crowley F, Debnath N, et al.

J Natl Cancer Inst

Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice

Park W, O'Connor CA, Bandlamudi C, Forman D, Chou JF, Umeda S, Reyngold M, Varghese AM, et al.

Clin Cancer Res